HALOZYME THERAPEUTICS INC
For the period ended Mar 31, 2025. Filed May 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
During the three months ended March 31, 2025, the following officer adopted Rule 10b5-1 trading arrangements (as such terms are defined pursuant to Item 408 of Regulation S-K) as noted in the table below.
| Trading Arrangement | ||||||
|---|---|---|---|---|---|---|
| Name and Title | Action(3) | Date | Rule 10b5-1* | Non-Rule 10b5-1** | Total Shares To Be Sold | Expiration Date |
| Helen Torley | Adoption | 3/21/2025 | X | 376,569 | (1) | The earlier of 12/12/2025 or the date all shares are sold |
| President and Chief Executive Officer | ||||||
| Helen Torley | Adoption | 3/21/2025 | X | 251,923 | (2) | The earlier of 7/31/2026 or the date all shares are sold |
| President and Chief Executive Officer | ||||||
- Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
** Non-Rule 10b5-1 trading arrangement as defined in Item 408(c) of Regulation S-K under the Exchange Act.
(1)Represents common shares to be sold following exercise of stock options with a ten-year term expiring in February 2026.
(2)Represents common shares to be sold following exercise of stock options with a ten-year term expiring in February 2027.
(3)The Rule 10b5-1 trading arrangements are sequential and do not overlap.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.